Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

Stock Price: $333.78

+10.16 (3.14%)

Updated Jun 2, 2023 08:00 PM GMT+0000

Featured app

Invest now

77% of retail CFD accounts lose money.

Overview

Financials

Statistics

Profile

Chart

Market Cap	85.97B
Revenue	9.21B
Gross Profit	8.11B
Shares Out	257.55M
EPS (ttm)	12.55
PE Ratio	26.3722
Forward PE	23.4058
Dividend Rate (ttm)	0.0000
Dividend Yield	0.0000

Trading Day	Jun 2
Last Price	$333.78
Previous Close	$323.62
Change ($)	10.16
Change (%)	3.14%
Day's Open	323
Day's Range	322.245 - 334.53
Day's Volume	1.57M
52 Week Range	243.17 - 354.46

About Vertex Pharmaceuticals, Inc.

vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. we discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (cf), a rare, life-threatening genetic disease.

in addition to clinical development programs in cf, vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. founded in 1989 in cambridge, massachusetts, our corporate headquarters is now located in boston’s innovation district, and our international headquarters is in london, united kingdom.

we currently employ 2,100 people in the united states, europe, canada and australia with nearly two-thirds of our staff dedicated to research and development. vertex is consistently recognized as one of the industry’s top places to work by science magazine, the boston globe, boston business journal and the san diego business jou.

News

Biotech is ‘oversold’: top stocks to capitalize on the pullback March 29, 2022

Quick info

Country

United States

Industry

Pharmaceutical Preparation Manufacturing

Sector

Manufacturing

Employees

4,800

CEO

Jeffrey Leiden

Address

50 Northern Ave
Boston
Massachusetts
02210-1862

Phone

16173416393

Website

vrtx.com

Ticker Symbol

VRTX

Exchange

NASDAQ Stock Exchange

Reporting Currency

USD

Vertex Pharmaceuticals, Inc. income statements (2022) (USD)

	August 2022
Total Revenue	2.20B
Cost of Revenue	261.80M
Gross Profit	1.93B
Research & Development	600.10M
Selling General & Admin	215.30M
Operating Expense	1.08B
Operating Income	1.12B
Other Income Expense Net	0
EBIT	1.12B
Interest Income	3.80M
Pretax Income	1.02B
Income Tax	213.90M
Minority Interest	0
Net Income	810.50M
Net Income Basic	810.50M

Vertex Pharmaceuticals, Inc. income statements (2020) (USD)

	October 2020	September 2020	June 2020	March 2020	March 2020
Total Revenue	1.54B	1.54B	1.52B	1.51B	1.51B
Cost of Revenue	186.18M	186.18M	184.52M	162.50M	162.50M
Gross Profit	1.35B	1.35B	1.33B	1.34B	1.34B
Research & Development	493.50M	490.97M	420.93M	448.53M	448.53M
Selling General & Admin	184.55M	184.55M	191.80M	182.26M	182.26M
Operating Expense	864.23M	861.71M	797.25M	793.28M	793.28M
Operating Income	674.04M	676.56M	720.87M	712.90M	712.90M
Other Income Expense Net	0	69.31M	103.90M	-55.37M	-55.37M
EBIT	674.04M	676.56M	720.87M	712.90M	712.90M
Interest Income	10.76M	13.86M	13.87M	14.14M	14.14M
Pretax Income	745.87M	745.87M	824.77M	657.53M	657.53M
Income Tax	78.44M	78.44M	-12.5M	54.78M	54.78M
Minority Interest	0	0	0	0	0
Net Income	667.43M	667.43M	837.27M	602.75M	602.75M
Net Income Basic	667.43M	667.43M	837.27M	602.75M	602.75M

Vertex Pharmaceuticals, Inc. income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	1.41B	0.94B	0.93B	851.60M
Cost of Revenue	185.01M	131.91M	135.74M	95.09M
Gross Profit	1.22B	807.61M	797.32M	756.50M
Research & Development	480.01M	555.95M	379.09M	339.49M
Selling General & Admin	195.28M	159.67M	156.50M	147.05M
Operating Expense	860.30M	847.54M	671.33M	581.63M
Operating Income	545.80M	91.99M	261.72M	269.97M
Other Income Expense Net	131.15M	-21.32M	65.42M	50.20M
EBIT	545.80M	91.99M	261.72M	269.97M
Interest Income	14.25M	14.55M	14.84M	14.87M
Pretax Income	676.95M	70.67M	327.14M	320.17M
Income Tax	93.72M	13.15M	59.71M	51.53M
Minority Interest	0	0	0	0
Net Income	583.23M	57.52M	267.43M	268.63M
Net Income Basic	583.23M	57.52M	267.43M	268.63M

Vertex Pharmaceuticals, Inc. income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	863.92M	782.81M	754.83M	640.80M
Cost of Revenue	122.29M	111.26M	104.38M	71.61M
Gross Profit	741.63M	671.56M	650.45M	569.19M
Research & Development	437.88M	330.51M	337.53M	310.55M
Selling General & Admin	153.21M	137.30M	137.30M	129.81M
Operating Expense	713.38M	579.06M	579.22M	511.97M
Operating Income	150.54M	203.75M	175.62M	128.83M
Other Income Expense Net	-118.04M	-67.24M	40.98M	85.82M
EBIT	150.54M	203.75M	175.62M	128.83M
Interest Income	4.77M	8.14M	10.11M	11.10M
Pretax Income	32.50M	136.51M	216.59M	214.64M
Income Tax	-1.49B	8.06M	10.34M	-12.66M
Minority Interest	-25.43M	-290K	-1.11M	17.04M
Net Income	1.55B	128.73M	207.30M	210.16M
Net Income Basic	1.55B	128.73M	207.30M	210.16M

Vertex Pharmaceuticals, Inc. income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	651.63M	578.17M	544.14M
Cost of Revenue	84.05M	72.87M	71.21M
Gross Profit	567.58M	505.29M	472.93M
Research & Development	306.66M	454.95M	289.45M
Selling General & Admin	134.79M	115.61M	127.25M
Operating Expense	525.51M	643.43M	487.91M
Operating Income	126.12M	-65.27M	56.23M
Other Income Expense Net	-13.68M	-351.9M	-20.72M
EBIT	126.12M	-65.27M	56.23M
Interest Income	12.55M	13.57M	14.66M
Pretax Income	112.44M	-417.17M	35.51M
Income Tax	10.26M	-125.9M	4.34M
Minority Interest	1.50M	-188.32M	13.17M
Net Income	100.59M	-102.95M	17.97M
Net Income Basic	100.59M	-102.95M	17.97M

Vertex Pharmaceuticals, Inc. balance sheet (2023) (USD)

	February 2023
Current Cash	10.78B
Receivables	1.44B
Inventory	460.60M
Current Assets	13.23B
Other Current Assets	553.50M
Short Term Investments	553.50M
Long Term Investments	4.92B
Property/Plant Equipment	1.11B
Good Will	N.A
Intangible Assets	603.60M
Tangible Assets (Net)	12.22B
Other Assets	521.80M
Total Assets	18.15B
Accounts Payable	303.90M
Other Current Liabilities	2.40B
Total Current Liabilities	2.74B
Total Liabilities	4.24B
Long Term Debt	430.80M
Current Long Term Debt	40.80M
Minority Interest	0
Common Stock	256.90M
Treasury Stock	0
Retained Earnings	6.52B
Capital Surplus	N.A
Shareholder Equity	13.91B
Other Liabilities	N.A

Vertex Pharmaceuticals, Inc. balance sheet (2022) (USD)

	August 2022
Current Cash	9.25B
Receivables	1.33B
Inventory	367.70M
Current Assets	11.50B
Other Current Assets	549.50M
Short Term Investments	549.50M
Long Term Investments	4.08B
Property/Plant Equipment	1.10B
Good Will	N.A
Intangible Assets	387M
Tangible Assets (Net)	10.54B
Other Assets	127.30M
Total Assets	15.58B
Accounts Payable	198M
Other Current Liabilities	2.36B
Total Current Liabilities	2.56B
Total Liabilities	3.65B
Long Term Debt	482.30M
Current Long Term Debt	0
Minority Interest	0
Common Stock	255.90M
Treasury Stock	0
Retained Earnings	4.77B
Capital Surplus	N.A
Shareholder Equity	11.93B
Other Liabilities	N.A

Vertex Pharmaceuticals, Inc. balance sheet (2020) (USD)

	October 2020	September 2020	June 2020	March 2020	March 2020
Current Cash	6.15B	N.A	4.84B	3.60B	3.60B
Receivables	791.92M	791.92M	791.77M	845.27M	845.27M
Inventory	245.46M	245.46M	219.22M	187.09M	187.09M
Current Assets	7.46B	7.19B	6.69B	5.45B	5.45B
Other Current Assets	270.02M	N.A	228.20M	215.10M	215.10M
Short Term Investments	270.02M	N.A	619.44M	596.98M	596.98M
Long Term Investments	3.84B	N.A	46.64M	48.40M	48.40M
Property/Plant Equipment	0.92B	0.92B	728.36M	736.30M	736.30M
Good Will	N.A	N.A	N.A	N.A	N.A
Intangible Assets	400M	N.A	400M	400M	400M
Tangible Assets (Net)	6.73B	8.13B	6.52B	5.46B	5.46B
Other Assets	372.29M	642.31M	129.92M	112.24M	112.24M
Total Assets	11.30B	11.30B	10.22B	8.89B	8.89B
Accounts Payable	107.79M	1.81B	101.45M	100.70M	100.70M
Other Current Liabilities	1.90B	N.A	1.70B	1.44B	1.44B
Total Current Liabilities	2B	1.81B	1.80B	1.54B	1.54B
Total Liabilities	3.17B	3.17B	2.70B	2.43B	2.43B
Long Term Debt	546.51M	587.77M	522.07M	532.95M	532.95M
Current Long Term Debt	0	N.A	N.A	N.A	N.A
Minority Interest	0	0	0	0	0
Common Stock	7.92B	260.17M	260.12M	259.08M	259.08M
Treasury Stock	0	N.A	N.A	N.A	N.A
Retained Earnings	254.48M	N.A	-412.96M	-1.25B	-1.25B
Capital Surplus	N.A	N.A	7.94B	7.70B	7.70B
Shareholder Equity	8.13B	8.13B	7.52B	6.46B	6.46B
Other Liabilities	N.A	N.A	N.A	N.A	N.A

Vertex Pharmaceuticals, Inc. balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	3.12B	3.40B	3.30B	2.89B
Receivables	633.52M	443.32M	464.90M	438.30M
Inventory	167.50M	162.31M	143.02M	136.70M
Current Assets	4.82B	4.78B	4.71B	4.18B
Other Current Assets	205.51M	168.49M	144.87M	130.01M
Short Term Investments	698.97M	598.39M	656.54M	584.15M
Long Term Investments	44.16M	74.70M	33.91M	N.A
Property/Plant Equipment	833.28M	794.44M	789.16M	803.13M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	400M	N.A	N.A	N.A
Tangible Assets (Net)	5.08B	4.81B	5.02B	4.67B
Other Assets	25.23M	5.28M	23.85M	39.04M
Total Assets	8.32B	7.51B	7.03B	6.54B
Accounts Payable	87.61M	92.53M	77.05M	82.26M
Other Current Liabilities	1.20B	1.25B	1.14B	0.98B
Total Current Liabilities	1.33B	1.39B	1.26B	1.11B
Total Liabilities	2.23B	2.26B	1.96B	1.82B
Long Term Debt	622.87M	604.54M	611.96M	623.87M
Current Long Term Debt	38.80M	37.06M	37.05M	35.73M
Minority Interest	0	0	0	0
Common Stock	258.99M	257.27M	256.67M	256.35M
Treasury Stock	N.A	N.A	N.A	N.A
Retained Earnings	-1.85B	-2.44B	-2.49B	-2.76B
Capital Surplus	7.94B	7.67B	7.56B	7.48B
Shareholder Equity	6.09B	5.25B	5.07B	4.72B
Other Liabilities	N.A	N.A	N.A	N.A

Vertex Pharmaceuticals, Inc. balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	2.65B	2.49B	2.15B	2.01B
Receivables	414.87M	379.76M	393.44M	327.29M
Inventory	124.36M	124.15M	115.03M	117.35M
Current Assets	3.84B	3.69B	3.41B	3.04B
Other Current Assets	135.64M	118.68M	122.69M	109.89M
Short Term Investments	518.11M	577.58M	622.40M	481.12M
Long Term Investments	N.A	N.A	N.A	N.A
Property/Plant Equipment	812.01M	808.35M	815.93M	800.67M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	N.A	29M	29M	29M
Tangible Assets (Net)	4.38B	2.86B	2.64B	2.35B
Other Assets	40.73M	46.49M	32.65M	31.80M
Total Assets	6.25B	4.62B	4.34B	3.95B
Accounts Payable	110.99M	92.15M	83.03M	74.06M
Other Current Liabilities	1B	888.85M	829.21M	736.33M
Total Current Liabilities	1.12B	0.99B	0.93B	827.31M
Total Liabilities	1.81B	1.69B	1.62B	1.52B
Long Term Debt	581.55M	576.53M	577.68M	578.21M
Current Long Term Debt	9.82M	11.51M	15.06M	16.92M
Minority Interest	-25.43M	-290K	-1.11M	17.04M
Common Stock	255.17M	255.61M	254.88M	254.87M
Treasury Stock	N.A	N.A	N.A	N.A
Retained Earnings	-2.99B	-4.54B	-4.67B	-4.88B
Capital Surplus	7.42B	7.44B	7.36B	7.31B
Shareholder Equity	4.44B	2.91B	2.69B	2.40B
Other Liabilities	N.A	N.A	N.A	N.A

Vertex Pharmaceuticals, Inc. balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	1.67B	1.39B	1.29B
Receivables	310.25M	263.49M	247.95M
Inventory	111.83M	98.19M	92.26M
Current Assets	2.65B	2.33B	2.18B
Other Current Assets	100.33M	152.24M	107.08M
Short Term Investments	423.25M	427.28M	445.52M
Long Term Investments	20.45M	20.45M	20.25M
Property/Plant Equipment	789.44M	759.98M	740.10M
Good Will	N.A	N.A	N.A
Intangible Assets	29M	29M	284.34M
Tangible Assets (Net)	1.98B	1.74B	1.62B
Other Assets	7.78M	10.54M	9.94M
Total Assets	3.55B	3.20B	3.29B
Accounts Payable	73.99M	77.14M	75.94M
Other Current Liabilities	710.74M	613.72M	531.29M
Total Current Liabilities	807.26M	710.74M	625.41M
Total Liabilities	1.50B	1.40B	1.42B
Long Term Debt	583.90M	567.31M	550.37M
Current Long Term Debt	22.53M	19.88M	18.18M
Minority Interest	1.50M	-188.32M	13.17M
Common Stock	253.25M	252.68M	250.77M
Treasury Stock	N.A	N.A	N.A
Retained Earnings	-5.12B	-5.22B	-5.12B
Capital Surplus	7.16B	7.03B	6.81B
Shareholder Equity	2.03B	1.79B	1.67B
Other Liabilities	N.A	N.A	N.A

Vertex Pharmaceuticals, Inc. cash flow (2023) (USD)

	February 2023
Net Income	818.90M
Depreciation	38.40M
Changes in Receivables	1.44B
Changes in Inventories	460.60M
Cash Change	10.78B
Cash Flow	1.08B
Capital Expenditures	-33.6M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	175.60M
Dividends Paid	N.A
Net Borrowings	-10.86B
Other Financing Cash Flows	N.A
Cash Flow Financing	40.20M
Exchange Rate Effect	N.A

Vertex Pharmaceuticals, Inc. cash flow (2022) (USD)

	October 2022	August 2022
Net Income	0.93B	810.50M
Depreciation	36.70M	37.30M
Changes in Receivables	1.39B	1.33B
Changes in Inventories	388.20M	367.70M
Cash Change	9.77B	9.25B
Cash Flow	0.96B	1.14B
Capital Expenditures	-54.2M	-53.3M
Investments	N.A	N.A
Investing Activity (other)	N.A	N.A
Total Investing Cash Flows	-384.2M	-61.5M
Dividends Paid	N.A	N.A
Net Borrowings	-10.06B	-9.32B
Other Financing Cash Flows	N.A	N.A
Cash Flow Financing	-60.2M	47.70M
Exchange Rate Effect	N.A	N.A

Vertex Pharmaceuticals, Inc. cash flow (2020) (USD)

	October 2020	September 2020	June 2020	March 2020
Net Income	667.43M	667.43M	837.27M	602.75M
Depreciation	80.16M	N.A	26.70M	26.82M
Changes in Receivables	149K	-149K	53.50M	-211.75M
Changes in Inventories	26.24M	N.A	-36.94M	-27.45M
Cash Change	700.29M	N.A	1.23B	481.28M
Cash Flow	2.76B	N.A	1.04B	815.70M
Capital Expenditures	-212.11M	N.A	-17.86M	-19.45M
Investments	N.A	N.A	89.78M	51.12M
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-144.36M	N.A	71.91M	31.67M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	-5.87B	N.A	-10.44M	-4.45M
Other Financing Cash Flows	N.A	N.A	-2.99M	-134.55M
Cash Flow Financing	-380.09M	N.A	120.03M	-359.43M
Exchange Rate Effect	N.A	N.A	3.27M	-6.65M

Vertex Pharmaceuticals, Inc. cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	583.23M	57.52M	267.43M	268.63M
Depreciation	26.26M	25.85M	27.70M	27.14M
Changes in Receivables	-190.2M	21.59M	-26.6M	-23.43M
Changes in Inventories	-18.77M	-20.11M	-12.04M	-13.14M
Cash Change	-283.91M	102.95M	400.11M	243.28M
Cash Flow	446.01M	334.79M	463.75M	324.78M
Capital Expenditures	-16.76M	-24.29M	-16.36M	-18.04M
Investments	28.16M	21.12M	-33.83M	-21.1M
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-896.99M	-249M	-50.19M	-39.14M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	-1.26M	-9.95M	-8.54M	-9.39M
Other Financing Cash Flows	131K	-125K	1.06M	3.62M
Cash Flow Financing	161.42M	20.36M	-13.02M	-41.99M
Exchange Rate Effect	5.65M	-3.2M	-430K	-378K

Vertex Pharmaceuticals, Inc. cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	1.55B	128.73M	207.30M	210.16M
Depreciation	18.83M	19.19M	18.06M	16.34M
Changes in Receivables	-35.12M	13.68M	-66.15M	-17.04M
Changes in Inventories	-7.5M	-15.1M	-1.16M	-8.21M
Cash Change	179.10M	332.98M	148.34M	338.20M
Cash Flow	314.58M	381.35M	321.70M	252.66M
Capital Expenditures	-15.72M	-20.91M	-29.61M	-29.28M
Investments	-2.36M	-28.98M	-86.69M	34.21M
Investing Activity (other)	-15M	N.A	N.A	N.A
Total Investing Cash Flows	-33.01M	-49.89M	-116.3M	4.93M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	-873K	-7.18M	-4.86M	369K
Other Financing Cash Flows	-707K	347K	2.26M	184K
Cash Flow Financing	-101.05M	2.08M	-51.21M	78.96M
Exchange Rate Effect	-1.43M	-555K	-5.86M	1.66M

Vertex Pharmaceuticals, Inc. cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	100.59M	-102.95M	17.97M
Depreciation	16.43M	15.23M	14.89M
Changes in Receivables	-46.76M	-15.54M	-39.99M
Changes in Inventories	-16.41M	-6.54M	-18.38M
Cash Change	280.13M	160.61M	239.51M
Cash Flow	227.51M	170.09M	181.65M
Capital Expenditures	-42.6M	-187.95M	-17.71M
Investments	21.14M	24.28M	-58.91M
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	-21.41M	-163.68M	-76.28M
Dividends Paid	N.A	N.A	N.A
Net Borrowings	25.23M	0.98M	-6.06M
Other Financing Cash Flows	1.37M	1.41M	1.45M
Cash Flow Financing	73.23M	152.71M	132.03M
Exchange Rate Effect	801K	1.50M	2.11M